Blood GlucoseOLIFTEANCT05397509
Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA)
A study testing Olive leaf tea in people with Blood Glucose, run by Instituto Politécnico de Bragança at 1 site in Portugal.
Trial summary
This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Blood Glucose
- What is being tested?
- Olive leaf tea
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 sitePortugal
- Study dates
- 29 Apr 2022to 30 Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- -
Who cannot join
- currently taking drugs interfering with glucose regulation
Trial locations and contacts
1 site in 1 country.
Portugal1 site, 1 recruiting
- Recruiting
escola Superior de Saúde
Bragança, 5300-253
Manuela Meireles, PhD, 273330984 ext. 3984, manuela.meireles@ipb.pt
About this study
This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal
Read the detailed description
This study is a double-blinded, randomized, placebo-controlled clinical trial with cross-over design.
- Conditions
- Blood Glucose
- Being tested
- Olive leaf tea, Placebo tea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Olive leaf teaOther
250 mL of Olive leaf tea and a high-glycemic breakfast
Placebo teaOther
250 mL of placebo tea and a high-glycemic breakfast
| Study group | Role | What they receive |
|---|---|---|
| Olive Leaf Tea | Experimental | Olive Leaf Tea Receives: Other: Olive leaf tea |
| Placebo tea | Placebo comparator | Placebo tea Receives: Other: Placebo tea |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood glucose
Area under the curve
Measured: 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2022
- Study start29 Apr 2022
- Primary completion30 Jun 2022 (estimated)
- Study completion30 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood GlucoseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Each participant will test one beverage on the first visit and the other one on the second visit. A wash-out period of two weeks will be done. Allocation of the first beverage to each participant is made by randomization.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Instituto Politécnico de Bragança
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manuela Meireles, Instituto Politécnico de Bragança
- Investigators
- Manuela Meireles, PhD, Principal investigator, Instituto Politécnico de Bragança
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05397509
- Sponsor's protocol ID
- 361221
- Acronym
- OLIFTEA
- Status last verified
- Apr 2022
- First submitted
- 25 May 2022
- Last updated
- 31 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA)
- ClinicalTrials.gov ID
- NCT05397509
- Acronym / sponsor ID
- OLIFTEA / 361221
- Conditions
- Blood Glucose
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Instituto Politécnico de BragançaUniversity, hospital or other
- Study start
- 29 Apr 2022 (actual)
- Primary completion
- 30 Jun 2022 (estimated)
- Study completion
- 30 Jun 2022 (estimated)
- First posted
- 31 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal
Detailed description
This study is a double-blinded, randomized, placebo-controlled clinical trial with cross-over design.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Each participant will test one beverage on the first visit and the other one on the second visit. A wash-out period of two weeks will be done. Allocation of the first beverage to each participant is made by randomization.
| Arm | Type | Receives |
|---|---|---|
| Olive Leaf Tea | Experimental | Other: Olive leaf teaOlive Leaf Tea |
| Placebo tea | Placebo comparator | Other: Placebo teaPlacebo tea |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (1 listed)
- currently taking drugs interfering with glucose regulation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Olive leaf tea250 mL of Olive leaf tea and a high-glycemic breakfast | Other | Olive Leaf Tea |
| Placebo tea250 mL of placebo tea and a high-glycemic breakfast | Other | Placebo tea |
Primary outcome
Blood glucose
Time frame: 120 minutes
Area under the curve
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2022.
Related trials for Blood Glucose
RecruitingObservational study
Glucose Levels and Outcomes in Women - Mid Pregnancy
Pregnancy
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruiting
A Nurse-Led Digital Coaching Program to Improve Blood Sugar Control in Adults With Type 2 Diabetes
Type 2 Diabetes Mellitus
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Not yet recruitingEarly Phase 1
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
Metabolic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manuela Meireles, PhD principal investigator
Instituto Politécnico de Bragança
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Olive leaf tea in people with Blood Glucose, run by Instituto Politécnico de Bragança at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 31 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manuela Meireles, PhD (273330984 ext. 3984, manuela.meireles@ipb.pt), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood glucose (time frame: 120 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2022.